One in four American adults has elevated LDL cholesterol. Most aren't at their target. The 2026 ACC/AHA Dyslipidemia Guidelines — published March 13, 2026 — brought major changes to LDL targets and treatment hierarchy. A board-certified internist explains what this means for you.
Why 2026 Changed the Cholesterol Conversation
The ACC/AHA hadn't issued a comprehensive cholesterol guideline update since 2018. The 2026 ACC/AHA Guideline for the Management of Dyslipidemia introduced several significant changes:
- Specific LDL-C targets are back: The 2018 guidelines moved away from numerical targets. The 2026 guidelines restore explicit LDL-C goals — making it much clearer when treatment is and isn't working
- PREVENT equations replace Pooled Cohort Equations: The old risk calculator overestimated 10-year cardiovascular risk by 40–50% in many populations. The new PREVENT calculator is more accurate
- Lp(a) measured once in every adult's lifetime: Now a strong recommendation — Lp(a) is an independent risk factor not captured by standard lipid panels
- Bempedoic acid (Nexletol®) has a formal place in the hierarchy: The CLEAR Outcomes trial (2023) established cardiovascular benefit for statin-intolerant patients
Your LDL Target Under the 2026 Guidelines
Your LDL-C target depends on cardiovascular risk category (PREVENT equation):
- Low risk (PREVENT <3%): LDL-C <100 mg/dL — lifestyle first; medication if persistent
- Borderline risk (3–<5%): LDL-C <100 mg/dL — lifestyle + consider statin if risk enhancers present (elevated Lp(a), family history, CKD)
- Intermediate risk (5–<10%): LDL-C <100 mg/dL — lifestyle + moderate-to-high statin; CAC scoring can guide borderline decisions
- High risk primary prevention (≥10%): LDL-C <70 mg/dL — high-intensity statin; add ezetimibe if target not reached
- Secondary prevention (prior MI, stroke, PAD): LDL-C <70 mg/dL — high-intensity statin + ezetimibe if needed
- Very high risk secondary prevention (multiple events or one event + high-risk features): LDL-C <55 mg/dL — maximum statin + ezetimibe; PCSK9 inhibitor if still above goal
Being "on a statin" is not the goal. Reaching your target is.
Statin Therapy: What the Evidence Says
Statins are the best-studied medications in cardiology. Large RCTs (4S, WOSCOPS, JUPITER, HOPE-3) establish that statins reduce major cardiovascular events 25–35% relative risk in primary prevention and up to 40% in secondary prevention. Key options:
- Atorvastatin 40–80 mg — high-intensity; ~$4/month generic
- Rosuvastatin 20–40 mg — high-intensity; excellent tolerability; low cost
- Pravastatin / lovastatin — moderate-intensity; preferred when CYP3A4 drug interactions are a concern
True myopathy with elevated CK is rare (<0.1%). Subjective muscle ache is more common (~10%) but usually resolves with dose reduction or switching statins. Important: simvastatin 80mg is no longer recommended per the 2026 guidelines due to high myopathy risk — if you're currently on it, discuss switching to atorvastatin or rosuvastatin.
Non-Statin Options (2026 Hierarchy)
- Ezetimibe: Reduces LDL 15–20%. Added to statin for high-risk patients not at goal. Generic, inexpensive.
- Bempedoic acid (Nexletol®/Nexlizet®): Non-muscle pathway; CLEAR Outcomes trial showed cardiovascular benefit. ~18% LDL reduction. First choice for genuine statin intolerance.
- PCSK9 inhibitors (alirocumab, evolocumab): Injectable; LDL reduction 50–60% on top of maximally tolerated statin. Reserved for very high-risk patients and FH.
- Inclisiran (Leqvio): siRNA every 6 months; ~50% LDL reduction. Emerging access via physician office administration.
- Vascepa® (icosapentaenoic acid): Reduces cardiovascular events in high-risk patients with TG ≥150 on statin (REDUCE-IT trial, 2018).
Lp(a): The Risk Factor Most Physicians Aren't Testing
Lipoprotein(a) is genetically determined, elevated in ~20% of the population, and roughly doubles cardiovascular risk independent of LDL. The 2026 guidelines recommend measuring it once during every adult's lifetime. If your Lp(a) is elevated (>50 mg/dL or >125 nmol/L), it upgrades your risk category and changes your LDL target. Most patients have never had this drawn. Your YourMD physician will order it at your initial visit.
Lab Workup
Initial: fasting lipid panel (12h fast), Lp(a), ApoB, TSH (secondary cause), comprehensive metabolic panel (liver baseline, kidney function), fasting glucose or HbA1c. After starting therapy: repeat lipid panel at 4–12 weeks. Once stable at goal: annual lipid panel. If muscle symptoms: CK promptly; stop statin and seek urgent care for severe symptoms with dark urine.
Telehealth Cholesterol Care at YourMD
YourMD Cholesterol Care ($99 initial, $49 follow-up, $25 refill) includes: PREVENT equation risk calculation, individualized LDL-C target, lab orders through Quest/LabCorp, prescriptions for statins, ezetimibe, bempedoic acid, fibrates, and Vascepa® as indicated, plus PA coordination for non-statin therapies.
Referral triggers: LDL-C >250 mg/dL (likely familial hypercholesterolemia — lipidology), TG ≥1,000 mg/dL (pancreatitis risk — urgent), failure to reach target on maximum oral therapy (PCSK9 inhibitor coordination), recent ACS or complex CVD (cardiology co-management).
Related: Telehealth for Hypertension · What Is Telehealth Internal Medicine?